GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (WBO:MRK) » Definitions » EV-to-Revenue
中文

Merck (WBO:MRK) EV-to-Revenue

: 5.88 (As of Today)
View and export this data going back to 2017. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Merck's enterprise value is €327,920 Mil. Merck's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €55,780 Mil. Therefore, Merck's EV-to-Revenue for today is 5.88.

The historical rank and industry rank for Merck's EV-to-Revenue or its related term are showing as below:

WBO:MRK' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.04   Med: 4.56   Max: 6.1
Current: 5.81

During the past 13 years, the highest EV-to-Revenue of Merck was 6.10. The lowest was 3.04. And the median was 4.56.

WBO:MRK's EV-to-Revenue is ranked worse than
80.43% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 2.3 vs WBO:MRK: 5.81

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-24), Merck's stock price is €118.80. Merck's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was €21.92. Therefore, Merck's PS Ratio for today is 5.42.


Merck EV-to-Revenue Historical Data

The historical data trend for Merck's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merck Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.04 5.33 4.49 5.05 5.06

Merck Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.05 5.02 5.55 4.84 5.06

Competitive Comparison

For the Drug Manufacturers - General subindustry, Merck's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck EV-to-Revenue Distribution

For the Drug Manufacturers industry and Healthcare sector, Merck's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Merck's EV-to-Revenue falls into.



Merck EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Merck's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=327919.834/55780.267
=5.88

Merck's current Enterprise Value is €327,920 Mil.
Merck's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €55,780 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck  (WBO:MRK) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Merck's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=118.80/21.924
=5.42

Merck's share price for today is €118.80.
Merck's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €21.92.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Merck EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Merck's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Merck (WBO:MRK) Business Description

Address
126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (WBO:MRK) Headlines

From GuruFocus

Q3 2023 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Q4 2022 Merck & Co Inc Earnings Call Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc To Host ESMO Call (Virtual) Transcript

By GuruFocus Research 01-23-2024

Merck & Co Inc Investor Event at ASCO 2023 Transcript

By GuruFocus Research 01-23-2024